Compare ASTRAZENECA PHARMA with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs STERLING BIOTECH - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA STERLING BIOTECH ASTRAZENECA PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 129.4 -0.4 - View Chart
P/BV x 36.3 0.0 254,937.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
STERLING BIOTECH
Dec-13
ASTRAZENECA PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,27811 12,171.4%   
Low Rs8833 25,958.8%   
Sales per share (Unadj.) Rs228.426.8 852.0%  
Earnings per share (Unadj.) Rs10.4-15.0 -69.3%  
Cash flow per share (Unadj.) Rs16.3-5.5 -297.7%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.854.9 180.0%  
Shares outstanding (eoy) m25.00267.87 9.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.70.3 1,824.3%   
Avg P/E ratio x104.2-0.5 -22,432.3%  
P/CF ratio (eoy) x66.4-1.3 -5,222.1%  
Price / Book Value ratio x10.90.1 8,636.9%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,0081,862 1,450.7%   
No. of employees `0001.41.4 100.1%   
Total wages/salary Rs m1,535547 280.8%   
Avg. sales/employee Rs Th4,210.95,303.3 79.4%   
Avg. wages/employee Rs Th1,132.2403.8 280.4%   
Avg. net profit/employee Rs Th191.1-2,959.0 -6.5%   
INCOME DATA
Net Sales Rs m5,7107,181 79.5%  
Other income Rs m12343 287.6%   
Total revenues Rs m5,8337,223 80.7%   
Gross profit Rs m463947 48.9%  
Depreciation Rs m1472,543 5.8%   
Interest Rs m04,377 0.0%   
Profit before tax Rs m438-5,931 -7.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179-1,924 -9.3%   
Profit after tax Rs m259-4,007 -6.5%  
Gross profit margin %8.113.2 61.5%  
Effective tax rate %40.832.4 125.9%   
Net profit margin %4.5-55.8 -8.1%  
BALANCE SHEET DATA
Current assets Rs m3,20914,335 22.4%   
Current liabilities Rs m2,07049,809 4.2%   
Net working cap to sales %20.0-494.0 -4.0%  
Current ratio x1.60.3 538.8%  
Inventory Days Days72403 17.9%  
Debtors Days Days35171 20.5%  
Net fixed assets Rs m79055,432 1.4%   
Share capital Rs m50268 18.7%   
"Free" reserves Rs m2,41913,935 17.4%   
Net worth Rs m2,46914,701 16.8%   
Long term debt Rs m09,478 0.0%   
Total assets Rs m4,60573,988 6.2%  
Interest coverage xNM-0.4-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.20.1 1,277.5%   
Return on assets %5.60.5 1,123.2%  
Return on equity %10.5-27.3 -38.5%  
Return on capital %17.7-6.4 -276.0%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m3001,860 16.1%   
Fx outflow Rs m2,01525 8,095.3%   
Net fx Rs m-1,7151,835 -93.5%   
CASH FLOW
From Operations Rs m881,719 5.1%  
From Investments Rs m-94-3,148 3.0%  
From Financial Activity Rs mNA1,426 0.0%  
Net Cashflow Rs m-6-3 167.6%  

Share Holding

Indian Promoters % 0.0 33.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.0 -  
FIIs % 15.7 9.9 158.6%  
ADR/GDR % 0.0 16.9 -  
Free float % 9.1 39.3 23.2%  
Shareholders   12,856 21,482 59.8%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

Buzzing Sectors Before Budget 2021(Fast Profits Daily)

Jan 12, 2021

The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.

Here's Why Smallcaps Could Be Your Best Investment in 2021(Profit Hunter)

Jan 12, 2021

Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 25, 2021 03:36 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - FRESENIUS KABI ONCO. COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS